Amia Capital LLP Nektar Therapeutics Transaction History

Amia Capital LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$15.77 - $19.03 $225,526 - $272,148	-14,301 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$16.59 - $24.79 $7,166 - $10,709	-432 Reduced 2.93%	14,301 $237,000
Q2 2020 Aug 14, 2020	SELL	$16.86 - $23.44 $136,717 - $190,074	-8,109 Reduced 35.5%	14,733 $341,000
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $60,571 - $117,040	-4,186 Reduced 15.49%	22,842 $408,000
Q4 2019 Feb 13, 2020	BUY	$15.87 - $23.12 $428,934 - $624,887	27,028 New	27,028 $583,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $212M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Amia Capital LLP, based on Form 13F filings with the SEC.

Stay updated on Amia Capital LLP with notifications on news.